Medtronic’s Evolut trial outcome could shift US TAVR market
Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction than SAPIEN. The post Medtronic’s Evolut trial outcome could shift US TAVR market appeared first on Medical Device Network.
Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction than SAPIEN.
The post Medtronic’s Evolut trial outcome could shift US TAVR market appeared first on Medical Device Network.
